ANI PHARMACEUTICALS, INC Undistributed Earnings, Diluted
ANI PHARMACEUTICALS, INC (ANIP) reported Undistributed Earnings, Diluted of $23.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Earnings Per Share › Undistributed Earnings (Loss) Available to Common Shareholders, Diluted
us-gaap:UndistributedEarningsDiluted · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC undistributed earnings, diluted for the quarter ending 2026-06-30 was $23.05M, a 214.10% increase year-over-year.
- ANI PHARMACEUTICALS, INC undistributed earnings, diluted for the quarter ending 2026-03-31 was $27.48M, a 100.01% increase year-over-year.
- ANI PHARMACEUTICALS, INC undistributed earnings, diluted for the quarter ending 2025-12-31 was $25.51M.
- ANI PHARMACEUTICALS, INC undistributed earnings, diluted for the quarter ending 2025-09-30 was $23.90M.
- ANI PHARMACEUTICALS, INC undistributed earnings, diluted for fiscal 2025 was $70.57M.
- ANI PHARMACEUTICALS, INC undistributed earnings, diluted for fiscal 2024 was -$20.15M, a 230.06% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC undistributed earnings, diluted for fiscal 2023 was $15.49M.
- ANI PHARMACEUTICALS, INC undistributed earnings, diluted for fiscal 2022 was -$49.52M.
| Period end | Undistributed Earnings, Diluted 3 month | Undistributed Earnings, Diluted 3 month as first filed | Undistributed Earnings, Diluted 6 month | Undistributed Earnings, Diluted 6 month as first filed | Undistributed Earnings, Diluted 9 month | Undistributed Earnings, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $23.05M 10-Q · filed 2026-08-07 | $50.55M 10-Q · filed 2026-08-07 | $76.05M derived: sum of 3 quarters · filed 2026-08-07 | $99.95M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2026-03-31 | $27.48M 10-Q · filed 2026-05-08 | $53.00M derived: sum of 2 quarters · filed 2026-05-08 | $76.90M derived: sum of 3 quarters · filed 2026-05-08 | $84.24M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-12-31 | $25.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $49.41M derived: sum of 2 quarters · filed 2026-02-27 | $56.75M derived: sum of 3 quarters · filed 2026-08-07 | $70.57M 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $23.90M 10-Q · filed 2025-11-07 | $31.24M derived: sum of 2 quarters · filed 2026-08-07 | $45.06M 10-Q · filed 2025-11-07 | $34.30M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $7.34M 10-Q · filed 2026-08-07 | $21.10M 10-Q · filed 2026-08-07 | $10.40M derived: sum of 3 quarters · filed 2026-08-07 | -$14.17M derived: sum of 4 quarters · filed 2026-08-07 | ||
| 2025-03-31 | $13.74M 10-Q · filed 2026-05-08 | $3.06M derived: sum of 2 quarters · filed 2026-05-08 | -$21.51M derived: sum of 3 quarters · filed 2026-05-08 | -$24.21M derived: sum of 4 quarters · filed 2026-05-08 | ||
| 2024-12-31 | -$10.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$35.25M derived: sum of 2 quarters · filed 2026-02-27 | -$37.95M derived: sum of 3 quarters · filed 2026-02-27 | -$20.15M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | -$24.57M 10-Q · filed 2025-11-07 | -$27.27M derived: sum of 2 quarters · filed 2025-11-07 | -$9.46M 10-Q · filed 2025-11-07 | -$10.54M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-06-30 | -$2.69M 10-Q · filed 2025-08-08 | $13.63M 10-Q · filed 2025-08-08 | $14.03M derived: sum of 3 quarters · filed 2026-02-27 | $22.68M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2024-03-31 | $16.02M 10-Q · filed 2025-05-09 | $16.72M derived: sum of 2 quarters · filed 2026-02-27 | $25.38M derived: sum of 3 quarters · filed 2026-02-27 | $30.63M derived: sum of 4 quarters · filed 2026-02-27 | ||
| 2023-12-31 | $701.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $9.35M derived: sum of 2 quarters · filed 2026-02-27 | $14.60M derived: sum of 3 quarters · filed 2026-02-27 | $15.49M 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $8.65M 10-Q · filed 2024-11-08 | $13.90M derived: sum of 2 quarters · filed 2024-11-08 | $14.79M 10-Q · filed 2024-11-08 | $10.17M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $5.25M 10-Q · filed 2024-08-06 | $5.84M 10-Q · filed 2023-08-09 | $6.16M 10-Q · filed 2024-08-06 | $6.87M 10-Q · filed 2023-08-09 | $1.52M derived: sum of 3 quarters · filed 2025-02-28 | -$7.49M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $920.00K 10-Q · filed 2024-05-10 | -$3.73M derived: sum of 2 quarters · filed 2025-02-28 | -$12.74M derived: sum of 3 quarters · filed 2025-02-28 | -$28.07M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2022-12-31 | -$4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$13.66M derived: sum of 2 quarters · filed 2025-02-28 | -$28.99M derived: sum of 3 quarters · filed 2025-02-28 | -$49.52M 10-K · filed 2025-02-28 | ||
| 2022-09-30 | -$9.01M 10-Q · filed 2023-11-08 | -$24.34M derived: sum of 2 quarters · filed 2023-11-08 | -$44.87M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | -$15.33M 10-Q · filed 2023-08-09 | -$35.87M 10-Q · filed 2023-08-09 | ||||
| 2021-12-31 | -$42.79M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |